STOCK TITAN

[Form 4] CAMP4 Therapeutics Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Camp4 Therapeutics Corp. (CAMP) filed a Form 4 detailing a routine director equity grant. On 06/25/2025, director Michael J. Higgins received a stock option covering 9,000 common shares at an exercise price of $1.56 per share. The option vests in full on the earlier of (i) the first anniversary of the grant date or (ii) the company’s next annual shareholders’ meeting, provided Mr. Higgins remains on the board. The option expires on 06/24/2035. Following the transaction, Mr. Higgins beneficially owns 9,000 derivative securities (options) and disclosed no additional direct or indirect common-stock holdings.
The filing was signed on 06/27/2025 by Josh Mandel-Brehm as Attorney-in-Fact.

Camp4 Therapeutics Corp. (CAMP) ha presentato un Modulo 4 relativo a una consueta assegnazione di azioni ai membri del consiglio. Il 25/06/2025, il direttore Michael J. Higgins ha ricevuto un opzione su azioni per 9.000 azioni ordinarie con un prezzo di esercizio di 1,56 $ per azione. L'opzione matura completamente al verificarsi del primo tra (i) il primo anniversario della data di assegnazione o (ii) la prossima assemblea annuale degli azionisti della società, a condizione che il Sig. Higgins rimanga nel consiglio di amministrazione. L'opzione scade il 24/06/2035. Dopo questa operazione, il Sig. Higgins detiene beneficiariamente 9.000 strumenti derivati (opzioni) e non ha dichiarato ulteriori partecipazioni dirette o indirette in azioni ordinarie.
Il documento è stato firmato il 27/06/2025 da Josh Mandel-Brehm in qualità di procuratore.

Camp4 Therapeutics Corp. (CAMP) presentó un Formulario 4 detallando una concesión rutinaria de acciones a un director. El 25/06/2025, el director Michael J. Higgins recibió una opción sobre 9,000 acciones comunes con un precio de ejercicio de $1.56 por acción. La opción se consolida en su totalidad en la fecha que ocurra primero entre (i) el primer aniversario de la fecha de concesión o (ii) la próxima junta anual de accionistas de la compañía, siempre que el Sr. Higgins continúe en la junta. La opción expira el 24/06/2035. Tras esta transacción, el Sr. Higgins posee beneficiosamente 9,000 valores derivados (opciones) y no declaró ninguna participación adicional directa o indirecta en acciones comunes.
El documento fue firmado el 27/06/2025 por Josh Mandel-Brehm como apoderado.

Camp4 Therapeutics Corp. (CAMP)는 이사 주식 부여에 관한 Form 4를 제출했습니다. 2025년 6월 25일, 이사 Michael J. Higgins는 주당 $1.56의 행사가격으로 9,000 보통주에 대한 스톡옵션을 받았습니다. 이 옵션은 (i) 부여일로부터 1주년 또는 (ii) 회사의 다음 연례 주주총회 중 먼저 도래하는 시점에 전액 베스팅되며, Higgins 이사가 이사회에 남아 있는 경우에 한합니다. 옵션 만료일은 2035년 6월 24일입니다. 이번 거래 이후 Higgins 이사는 9,000개의 파생증권(옵션)을 실질적으로 보유하고 있으며, 추가적인 직접 또는 간접 보통주 보유는 공개하지 않았습니다.
해당 서류는 2025년 6월 27일 Josh Mandel-Brehm 대리인이 서명하였습니다.

Camp4 Therapeutics Corp. (CAMP) a déposé un formulaire 4 détaillant une attribution d’actions habituelle à un administrateur. Le 25/06/2025, l’administrateur Michael J. Higgins a reçu une option d’achat portant sur 9 000 actions ordinaires à un prix d’exercice de 1,56 $ par action. L’option devient totalement acquise à la date la plus proche entre (i) le premier anniversaire de la date d’attribution ou (ii) la prochaine assemblée générale annuelle de la société, à condition que M. Higgins reste au conseil d’administration. L’option expire le 24/06/2035. À la suite de cette opération, M. Higgins détient de manière bénéficiaire 9 000 titres dérivés (options) et n’a déclaré aucune autre participation directe ou indirecte en actions ordinaires.
Le document a été signé le 27/06/2025 par Josh Mandel-Brehm en tant que mandataire.

Camp4 Therapeutics Corp. (CAMP) reichte ein Formular 4 ein, das eine routinemäßige Aktienzuteilung an einen Direktor beschreibt. Am 25.06.2025 erhielt Direktor Michael J. Higgins eine Aktienoption über 9.000 Stammaktien zu einem Ausübungspreis von 1,56 $ pro Aktie. Die Option wird vollständig fällig am früheren Zeitpunkt von (i) dem ersten Jahrestag des Zuteilungsdatums oder (ii) der nächsten jährlichen Hauptversammlung der Gesellschaft, vorausgesetzt, Herr Higgins bleibt im Vorstand. Die Option läuft am 24.06.2035 ab. Nach der Transaktion besitzt Herr Higgins wirtschaftlich 9.000 derivative Wertpapiere (Optionen) und gab keine weiteren direkten oder indirekten Stammaktienbestände an.
Die Einreichung wurde am 27.06.2025 von Josh Mandel-Brehm als Bevollmächtigter unterzeichnet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Standard board option grant; no governance red flags or material investor impact.

This Form 4 documents a routine, board-service stock-option award to director Michael J. Higgins. The single grant of 9,000 options at $1.56 aligns with typical small-cap governance practices and includes a one-year or next-AGM vesting cliff, incentivising continued board participation without creating excessive dilution. No other equity movements or accelerated vesting provisions are disclosed, suggesting straightforward compliance with Section 16 reporting obligations.

TL;DR: Transaction is immaterial to valuation; neutral signal for CAMP shares.

The option grant represents a negligible fraction of CAMP’s outstanding share count and conveys no insight into operational performance or insider sentiment, as it is compensation-related rather than open-market buying. With no purchase of existing shares and no sale activity, the filing should have minimal trading impact. Investors may note the $1.56 strike as a reference point for management’s long-term value expectations, but overall, it neither strengthens nor weakens the investment thesis.

Camp4 Therapeutics Corp. (CAMP) ha presentato un Modulo 4 relativo a una consueta assegnazione di azioni ai membri del consiglio. Il 25/06/2025, il direttore Michael J. Higgins ha ricevuto un opzione su azioni per 9.000 azioni ordinarie con un prezzo di esercizio di 1,56 $ per azione. L'opzione matura completamente al verificarsi del primo tra (i) il primo anniversario della data di assegnazione o (ii) la prossima assemblea annuale degli azionisti della società, a condizione che il Sig. Higgins rimanga nel consiglio di amministrazione. L'opzione scade il 24/06/2035. Dopo questa operazione, il Sig. Higgins detiene beneficiariamente 9.000 strumenti derivati (opzioni) e non ha dichiarato ulteriori partecipazioni dirette o indirette in azioni ordinarie.
Il documento è stato firmato il 27/06/2025 da Josh Mandel-Brehm in qualità di procuratore.

Camp4 Therapeutics Corp. (CAMP) presentó un Formulario 4 detallando una concesión rutinaria de acciones a un director. El 25/06/2025, el director Michael J. Higgins recibió una opción sobre 9,000 acciones comunes con un precio de ejercicio de $1.56 por acción. La opción se consolida en su totalidad en la fecha que ocurra primero entre (i) el primer aniversario de la fecha de concesión o (ii) la próxima junta anual de accionistas de la compañía, siempre que el Sr. Higgins continúe en la junta. La opción expira el 24/06/2035. Tras esta transacción, el Sr. Higgins posee beneficiosamente 9,000 valores derivados (opciones) y no declaró ninguna participación adicional directa o indirecta en acciones comunes.
El documento fue firmado el 27/06/2025 por Josh Mandel-Brehm como apoderado.

Camp4 Therapeutics Corp. (CAMP)는 이사 주식 부여에 관한 Form 4를 제출했습니다. 2025년 6월 25일, 이사 Michael J. Higgins는 주당 $1.56의 행사가격으로 9,000 보통주에 대한 스톡옵션을 받았습니다. 이 옵션은 (i) 부여일로부터 1주년 또는 (ii) 회사의 다음 연례 주주총회 중 먼저 도래하는 시점에 전액 베스팅되며, Higgins 이사가 이사회에 남아 있는 경우에 한합니다. 옵션 만료일은 2035년 6월 24일입니다. 이번 거래 이후 Higgins 이사는 9,000개의 파생증권(옵션)을 실질적으로 보유하고 있으며, 추가적인 직접 또는 간접 보통주 보유는 공개하지 않았습니다.
해당 서류는 2025년 6월 27일 Josh Mandel-Brehm 대리인이 서명하였습니다.

Camp4 Therapeutics Corp. (CAMP) a déposé un formulaire 4 détaillant une attribution d’actions habituelle à un administrateur. Le 25/06/2025, l’administrateur Michael J. Higgins a reçu une option d’achat portant sur 9 000 actions ordinaires à un prix d’exercice de 1,56 $ par action. L’option devient totalement acquise à la date la plus proche entre (i) le premier anniversaire de la date d’attribution ou (ii) la prochaine assemblée générale annuelle de la société, à condition que M. Higgins reste au conseil d’administration. L’option expire le 24/06/2035. À la suite de cette opération, M. Higgins détient de manière bénéficiaire 9 000 titres dérivés (options) et n’a déclaré aucune autre participation directe ou indirecte en actions ordinaires.
Le document a été signé le 27/06/2025 par Josh Mandel-Brehm en tant que mandataire.

Camp4 Therapeutics Corp. (CAMP) reichte ein Formular 4 ein, das eine routinemäßige Aktienzuteilung an einen Direktor beschreibt. Am 25.06.2025 erhielt Direktor Michael J. Higgins eine Aktienoption über 9.000 Stammaktien zu einem Ausübungspreis von 1,56 $ pro Aktie. Die Option wird vollständig fällig am früheren Zeitpunkt von (i) dem ersten Jahrestag des Zuteilungsdatums oder (ii) der nächsten jährlichen Hauptversammlung der Gesellschaft, vorausgesetzt, Herr Higgins bleibt im Vorstand. Die Option läuft am 24.06.2035 ab. Nach der Transaktion besitzt Herr Higgins wirtschaftlich 9.000 derivative Wertpapiere (Optionen) und gab keine weiteren direkten oder indirekten Stammaktienbestände an.
Die Einreichung wurde am 27.06.2025 von Josh Mandel-Brehm als Bevollmächtigter unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Higgins Michael J

(Last) (First) (Middle)
C/O CAMP4 THERAPEUTICS CORPORATION
ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)
CAMBRIDGE MA 02139

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.56 06/25/2025 A 9,000 (1) 06/24/2035 Common Stock 9,000 $0 9,000 D
Explanation of Responses:
1. The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date.
Remarks:
/s/ Josh Mandel-Brehm, as Attorney-in-Fact 06/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CAMP director Michael J. Higgins report on Form 4?

Grant of an option for 9,000 CAMP common shares at a $1.56 exercise price.

When do the 9,000 CAMP options granted to Michael J. Higgins vest?

They vest fully on the earlier of one year from 06/25/2025 or the next annual meeting.

What is the expiration date of the CAMP options issued to the director?

The options expire on 06/24/2035.

Did the Form 4 disclose any purchase or sale of CAMP common stock?

No. The filing shows only a derivative (option) grant; no common shares were bought or sold.

How many derivative securities does Michael J. Higgins own after the transaction?

He beneficially owns 9,000 stock options following the reported grant.
Camp4 Therapeutics Corp.

NASDAQ:CAMP

CAMP Rankings

CAMP Latest News

CAMP Latest SEC Filings

CAMP Stock Data

31.65M
11.81M
35.4%
56.97%
1.63%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE